oral pan-coronavirus antiviral, rev. covalent

Ph. III candidate for COVID-19 (300 mg BID)

from SARS-CoV-1 inhibitor (WO2005113580)

Science

Pfizer Worldwide Research

Chemical structure of Pfizer’s PF-07321332 (API of Paxlovid)

1.  This month’s cover molecule, Pfizer’s PF-07321332 (API of Paxlovid) is an oral, reversible covalent SARS-CoV-2 main protease inhibitor, which has been submitted to the FDA by Pfizer for emergency approval…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: